EGFR and non-small cell lung carcinoma: FLAURA clinical trial (NCT02296125) comparing osimertinib to erlotinib or gefitinib as a first-line treatment in advanced NSCLC patients with EGFR mutations revealed that osimertinib significantly improved PFS, establishing it as the preferential first-line treatment option (24, 48, 49).